961 related articles for article (PubMed ID: 33527237)
1. Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Caro L; Prueksaritanont T; Fandozzi CM; Feng HP; Guo Z; Wolford D; Panebianco D; Fraser IP; Levine V; Swearingen D; Butterton JR; Iwamoto M; Yeh WW
Clin Drug Investig; 2021 Feb; 41(2):133-147. PubMed ID: 33527237
[TBL] [Abstract][Full Text] [Related]
2. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.
Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Barbour A; Reitmann C; Jumes P; Gilmartin J; Wolford D; Valesky R; Martinho M; Butterton JR; Iwamoto M; Fraser I; Webster L; Yeh WW
Clin Transl Sci; 2018 Nov; 11(6):562-572. PubMed ID: 30040871
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.
Caro L; Wenning L; Feng HP; Guo Z; Du L; Bhagunde P; Fandozzi C; Panebianco D; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
Eur J Clin Pharmacol; 2019 May; 75(5):665-675. PubMed ID: 30680407
[TBL] [Abstract][Full Text] [Related]
4. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
Liu CJ; Tseng KC; Lo CC; Tseng IH; Cheng PN
J Formos Med Assoc; 2020 May; 119(5):933-940. PubMed ID: 31594667
[TBL] [Abstract][Full Text] [Related]
5. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
Marshall WL; Feng HP; Caro L; Talaty J; Guo Z; Huang X; Panebianco D; Ma J; Mangin E; O'Reilly TE; Butterton JR; Yeh WW
Eur J Clin Pharmacol; 2017 May; 73(5):593-600. PubMed ID: 28233047
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
Feng HP; Guo Z; Fandozzi C; Panebianco D; Caro L; Wolford D; Dreyer DP; Valesky R; Martinho M; Rizk ML; Iwamoto M; Yeh WW
Clin Pharmacol Drug Dev; 2019 Oct; 8(7):952-961. PubMed ID: 31173673
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers.
Feng HP; Caro L; Fandozzi CM; Guo Z; Talaty J; Wolford D; Panebianco D; Iwamoto M; Butterton JR; Yeh WW
J Clin Pharmacol; 2018 May; 58(5):666-673. PubMed ID: 29329497
[TBL] [Abstract][Full Text] [Related]
8. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.
Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Reitmann C; Jumes P; Wolford D; Fraser I; Valesky R; Martinho M; Butterton JR; Iwamoto M; Webster L; Yeh WW
Clin Transl Sci; 2018 Nov; 11(6):553-561. PubMed ID: 30040872
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Brown A; Hézode C; Zuckerman E; Foster GR; Zekry A; Roberts SK; Lahser F; Durkan C; Badshah C; Zhang B; Robertson M; Wahl J; Barr E; Haber B;
J Viral Hepat; 2018 May; 25(5):457-464. PubMed ID: 29152828
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review.
Liu J; Guo M; Ke L; You R
Front Public Health; 2022; 10():836986. PubMed ID: 35646774
[TBL] [Abstract][Full Text] [Related]
11. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
Jacobson IM; Poordad F; Firpi-Morell R; Everson GT; Verna EC; Bhanja S; Hwang P; Caro L; Robertson M; Charles ED; Platt H
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00007. PubMed ID: 30939489
[TBL] [Abstract][Full Text] [Related]
12. Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor.
Caro L; Wenning L; Guo Z; Fraser IP; Fandozzi C; Talaty J; Panebianco D; Ho M; Uemura N; Reitmann C; Angus P; Gane E; Marbury T; Smith WB; Iwamoto M; Butterton JR; Yeh WW
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947470
[TBL] [Abstract][Full Text] [Related]
13. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
Kumada H; Suzuki Y; Karino Y; Chayama K; Kawada N; Okanoue T; Itoh Y; Mochida S; Toyoda H; Yoshiji H; Takaki S; Yatsuzuka N; Yodoya E; Iwasa T; Fujimoto G; Robertson MN; Black S; Caro L; Wahl J
J Gastroenterol; 2017 Apr; 52(4):520-533. PubMed ID: 27873094
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
Elbasha EH; Robertson MN; Nwankwo C
Aliment Pharmacol Ther; 2017 Feb; 45(3):455-467. PubMed ID: 27910116
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
Nangia G; Vierling JM; Kwo P; Brown DD; Klopfer SO; Robertson MN; Haber BA; Reddy KR
J Viral Hepat; 2020 Nov; 27(11):1222-1233. PubMed ID: 32594612
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
Elbasha E; Greaves W; Roth D; Nwankwo C
J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
[TBL] [Abstract][Full Text] [Related]
20. Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.
Macías J; Téllez F; de Los Santos I; Morano LE; Merino D; Granados R; Vera-Mendez F; González-Serna A; Campo-Moneo E; García-Fraile L; García F; Real LM; Pineda JA;
J Viral Hepat; 2021 Jun; 28(6):878-886. PubMed ID: 33721377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
